Diadexus, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $4,571,000, loss from operations of $2,886,000, loss before income tax of $3,345,000, net loss of $3,348,000 or $0.87 per basic and diluted share compared to the total revenues of $7,676,000, loss from operations of $249,000, loss before income tax of $441,000, net loss of $441,000 or $0.12 per basic and diluted share for the same quarter a year ago. The decrease in total revenues is primarily attributable to lower PLAC ELISA product sales and a decrease in service revenues related to a GSK agreement which completed during the fourth quarter of 2014.

For the six months period, the company reported total revenues of $10,098,000, loss from operations of $3,394,000, loss before income tax of $4,304,000, net loss of $4,318,000 or $1.13 per basic and diluted share compared to the total revenues of $13,111,000, loss from operations of $4,117,000, loss before income tax of $4,529,000, net loss of $4,541,000 or $1.24 per basic and diluted share for the same period a year ago. The decrease in total revenues is primarily due to lower PLAC ELISA product sales and a decrease in service revenues related to a GSK agreement, which completed during the fourth quarter of 2014.

Due to the Health Diagnostics Laboratory bankruptcy, and the accompanying uncertainty around their ongoing business operations, the company is rescinding its previously stated revenue guidance for 2015. The Company will not be providing an outlook for 2015 at this time.